Cellebrite DI (CLBT) financial statements
Cellebrite DI reported revenue of $476M in fiscal 2025, up 18.5% a year over 6 years.
Net income was $78M and the operating margin 14.0%, against -0.9% in 2019.
Free cash flow was $160M.
The diluted share count rose 106% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Cellebrite DI's 10-K filings with the SEC.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $172M | $195M | $246M | $271M | $325M | $401M | $476M |
| Cost of revenue | $36M | $38M | $43M | $51M | $53M | $63M | $75M |
| Gross profit | $136M | $157M | $204M | $220M | $272M | $339M | $401M |
| Research and development | $47M | $54M | $66M | $81M | $84M | $98M | $114M |
| Selling, general and admin | $91M | $93M | $124M | $138M | $154M | $183M | $220M |
| Operating income | -$2M | $9M | $14M | $1M | $33M | $57M | $66M |
| Pre-tax income | $1M | $11M | $82M | $121M | -$76M | -$276M | $91M |
| Income tax | $3M | $6M | $11M | -$45,000 | $6M | $7M | $12M |
| Net income | -$2M | $6M | $71M | $121M | -$81M | -$283M | $78M |
| EPS (diluted) | -$0.08 | -$0.08 | $0.44 | $0.59 | -$0.43 | -$1.35 | $0.31 |
| Diluted shares | 122M | 124M | 162M | 195M | 190M | 209M | 250M |
| Gross margin | 79.2% | 80.6% | 82.7% | 81.3% | 83.6% | 84.4% | 84.2% |
| Operating margin | -0.9% | 4.7% | 5.6% | 0.4% | 10.2% | 14.2% | 14.0% |
| Net margin | -1.1% | 3.0% | 29.0% | 44.6% | -24.9% | -70.5% | 16.5% |
Balance sheet
Fiscal years, from Cellebrite DI's 10-K filings with the SEC.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $82M | $129M | $146M | $132M | $228M | $293M | $276M |
| Receivables | — | $66M | $68M | $79M | $77M | $82M | $105M |
| Inventory | — | $5M | $7M | $10M | $10M | $9M | $8M |
| Total current assets | — | $324M | $273M | $296M | $422M | $568M | $576M |
| Property, plant and equipment | — | $16M | $17M | $17M | $16M | $17M | $22M |
| Goodwill | — | $9M | $27M | $27M | $27M | $29M | $120M |
| Total assets | — | $364M | $340M | $403M | $533M | $691M | $939M |
| Total current liabilities | — | $159M | $187M | $208M | $254M | $296M | $370M |
| Total liabilities | — | $199M | $413M | $329M | $499M | $355M | $455M |
| Shareholders' equity | $59M | $64M | -$73M | $74M | $34M | $336M | $484M |
| Net debt | -$82M | -$129M | -$146M | -$88M | -$190M | -$192M | -$124M |
Cash flow
Fiscal years, from Cellebrite DI's 10-K filings with the SEC.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $16M | $67M | $36M | $21M | $102M | $132M | $174M |
| Capital spending | $6M | $6M | $5M | $7M | $5M | $9M | $13M |
| Free cash flow | $10M | $60M | $31M | $14M | $97M | $124M | $160M |
| Stock-based compensation | $13M | $7M | $6M | $14M | $19M | $31M | $45M |
| Dividends paid | $25M | $10M | $100M | $0 | $0 | — | — |
| Share buybacks (net) | -$808,000 | -$85,000 | $0 | $0 | — | — | — |
| Free cash flow margin | 5.8% | 31.0% | 12.6% | 5.1% | 29.8% | 30.8% | 33.7% |
| Dividends per share | $0.21 | $0.08 | $0.62 | — | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for CLBT.
Open CLBT in InvestinglyQuestions
What was Cellebrite DI's revenue in 2025?
$476M in fiscal 2025, from its 10-K filing.
How much free cash flow does Cellebrite DI generate?
$160M in fiscal 2025 (operating cash flow minus capital spending).
From Cellebrite DI's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.